Glendon E. French is recorded as Board Member and CEO at Pulmonx Corp (LUNG). The newest filing on record that lists Glendon E. French as Board Member and CEO at Pulmonx Corp (LUNG) is dated April 22, 2026. Pulmonx Corp reported in an 8-K filed October 27, 2025 that Glendon E. French was appointed the Board. Pulmonx Corp reported in an 8-K filed October 27, 2025 that Glendon E. French was appointed President and Chief Executive Officer, effective October 27, 2025. Pulmonx Corp reported in an 8-K filed February 21, 2024 that Glendon E. French resigned as President and Chief Executive Officer, effective March 15, 2024. The proxy statement of Pulmonx Corp reports total compensation of $3,543,520 for Glendon E. French in fiscal 2025, including a base salary of $116,186. Disclosed compensation is on record for 7 fiscal years. Glendon E. French has spoken on 1 earnings call across 1 company, most recently for Pulmonx Corp on July 29, 2026. Pulmonx Corp is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at Pulmonx Corp includes Glendon French (CEO and Board Member), Steven S. Williamson (CEO and Board Member), Derrick Sung (CFO and COO) and 4 others.
“You will also be appointed to the Board.”
Pulmonx Corp Form 8-K, filed October 27, 2025
· Read the filing
“On October 21, 2025, the Company's Board of Directors appointed Glendon E. French as the Company's President and Chief Executive Officer as of the Effective Date.”
Pulmonx Corp Form 8-K, filed October 27, 2025
· Read the filing
Glendon E. French on recent calls
“Here with me is Derek Sung, our Chief Operating Officer and Chief Financial Officer. Overall, we are very pleased with the progress we are making against our three key priorities of re-accelerating sales growth, driving near-term operating leverage, and advancing our market expanding clinical initiatives.”
